ONWARD MEDICAL N.V. Financials Onward Medical N.V.
Equities
ONWD
NL0015000HT4
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.69 EUR | +1.08% |
|
-7.68% | +51.29% |
| Apr. 25 | Onward Medical N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 02 | Onward Medical Seeks US FDA Nod to Market Spinal Cord Stimulation Therapy | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 307.9 | 187.7 | 162.4 | 162.4 | - |
| Enterprise Value (EV) 1 | 307.9 | 187.7 | 150.3 | 171.1 | 216.3 |
| P/E ratio | - | -5.71 x | -4.29 x | -4.19 x | -3.48 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 220 x | 89.4 x | 90.2 x | 32.8 x | 13.9 x |
| EV / Revenue | 220 x | 89.4 x | 83.5 x | 34.6 x | 18.5 x |
| EV / EBITDA | -10.9 x | - | -4.68 x | -5.03 x | -4.7 x |
| EV / FCF | -15.4 x | - | -4.67 x | -5.68 x | -5.79 x |
| FCF Yield | -6.48% | - | -21.4% | -17.6% | -17.3% |
| Price to Book | - | - | 6.51 x | 29.3 x | -4.89 x |
| Nbr of stocks (in thousands) | 30,184 | 30,184 | 34,629 | 34,629 | - |
| Reference price 2 | 10.20 | 6.220 | 4.690 | 4.690 | 4.690 |
| Announcement Date | 4/26/22 | 3/27/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.4 | 2.1 | 1.8 | 4.95 | 11.68 |
| EBITDA 1 | - | -28.2 | - | -32.12 | -34.02 | -46.03 |
| EBIT 1 | - | -28.53 | -32 | -32.12 | -34.08 | -40.85 |
| Operating Margin | - | -2,038% | -1,523.81% | -1,784.72% | -688.59% | -349.89% |
| Earnings before Tax (EBT) 1 | - | - | -33.6 | -31.17 | -32.33 | -35 |
| Net income 1 | -20.01 | - | -32.8 | -32.98 | -35.35 | -42.55 |
| Net margin | - | - | -1,561.9% | -1,831.94% | -714.14% | -364.45% |
| EPS 2 | -5.550 | - | -1.090 | -1.092 | -1.120 | -1.347 |
| Free Cash Flow 1 | - | -19.96 | - | -32.17 | -30.1 | -37.33 |
| FCF margin | - | -1,426.07% | - | -1,787.04% | -608.08% | -319.77% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 10/11/21 | 4/26/22 | 3/27/23 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 8.67 | 53.9 |
| Net Cash position 1 | - | - | - | 12.1 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.2547 x | -1.171 x |
| Free Cash Flow 1 | - | -20 | - | -32.2 | -30.1 | -37.3 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | 0.7200 | 0.1600 | -0.9600 |
| Cash Flow per Share 2 | - | - | - | -1.250 | -1.450 | -2.140 |
| Capex 1 | - | 0.09 | - | 0.35 | 0.23 | 0.88 |
| Capex / Sales | - | 6.5% | - | 19.44% | 4.55% | 7.49% |
| Announcement Date | 10/11/21 | 4/26/22 | 3/27/23 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.69
EUR
Average target price
13.85
EUR
Spread / Average Target
+195.31%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +51.29% | 173M | |
| +73.17% | 12.38B | |
| -18.74% | 7.92B | |
| +16.15% | 7.2B | |
| +4.81% | 5.84B | |
| +5.99% | 5.01B | |
| +27.07% | 4.53B | |
| -21.67% | 3.88B | |
| -40.82% | 2.23B | |
| +1.49% | 2.02B |
- Stock Market
- Equities
- ONWD Stock
- Financials Onward Medical N.V.
